Inhibrx Biosciences, Inc. (INBX) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Inhibrx Biosciences, Inc. (INBX) trades at a price-to-earnings ratio of 0.6x, with a stock price of $74.13 and trailing twelve-month earnings per share of $-10.02.
The current P/E is 410% above its 5-year average of 0.1x. Over the past five years, INBX's P/E has ranged from a low of 0.1x to a high of 0.1x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, INBX trades at a 97% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, INBX trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our INBX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Oncology Therapeutics Developers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
INCYIncyte Corporation | $20B | 15.8 | - | +4173%Best |
GMABGenmab A/S | $18B | 15.4 | 0.53 | +84% |
EXELExelixis, Inc. | $12B | 15.8 | 0.31Best | +58% |
INBXInhibrx Biosciences, Inc. | $1B | 0.6Lowest | - | +2377% |
BBOTBridgeBio Oncology Therapeutics Inc. | $794M | 21.8 | - | - |
PBYIPuma Biotechnology, Inc. | $287M | 9.3 | - | -2% |
CHRSCoherus Oncology, Inc. | $194M | 6.7 | - | +110% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $13.99 | $116.53 | 0.1x | -4% |
| FY2024 Q4 | $15.40 | $117.89 | 0.1x | +5% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $15.66 | $119.47 | 0.1x | +5% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $14.17 | $121.21 | 0.1x | -6% |
Average P/E for displayed period: 0.1x
See INBX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INBX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare INBX vs AGIO
See how INBX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is INBX stock overvalued or undervalued?
INBX trades at 0.6x P/E, above its 5-year average of 0.1x. The 100th percentile ranking indicates a premium to historical valuation.
How does INBX's valuation compare to peers?
Inhibrx Biosciences, Inc. P/E of 0.6x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is INBX's PEG ratio?
INBX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.